The relevant paragraph in the Doha Declaration recognises that WTO members with insufficient, or no manufacturing capacity, in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS agreement.
The relevant paragraph in the Doha Declaration recognises that WTO members with insufficient, or no manufacturing capacity, in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS agreement.